Yahalom, Gilad
Fay-Karmon, Tsvia
Livneh, Vered
Israeli-Korn, Simon
Ephraty, Lilach
Hassin-Baer, Sharon
Article History
Received: 17 February 2021
Revised: 17 May 2021
Accepted: 20 May 2021
First Online: 29 May 2021
Declarations
:
: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board of Sheba Medical Center (protocol code 7080–20, date of approval 11.06.2020).
: Since this study is a retrospective one, the requirement for informed consent contingent on a de-identified analysis of the study database was waived.
: Prof. Sharon Hassin-Baer, Dr. Simon Israeli-Korn, and Dr. Gilad Yahalom received consultancy fees from Abbvie Biopharmaceuticals Inc. and Medison Pharma. No other disclosures were reported.